These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33714020)

  • 41. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
    Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
    Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
    Li DD; Lv PC; Zhang H; Zhang HJ; Hou YP; Liu K; Ye YH; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(16):5012-22. PubMed ID: 21763148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives.
    Khodair AI; Alsafi MA; Nafie MS
    Carbohydr Res; 2019 Dec; 486():107832. PubMed ID: 31622868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
    Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
    Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
    Ahmed MF; Belal A
    Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
    Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
    Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
    Tu Y; OuYang Y; Xu S; Zhu Y; Li G; Sun C; Zheng P; Zhu W
    Bioorg Med Chem; 2016 Apr; 24(7):1495-503. PubMed ID: 26906472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
    Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
    Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
    Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.